{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:55:44Z","timestamp":1773294944155,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1038\/s41416-018-0225-4","type":"journal-article","created":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T11:01:44Z","timestamp":1539342104000},"page":"1421-1427","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study"],"prefix":"10.1038","volume":"119","author":[{"given":"Vasily","family":"Giannakeas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne M.","family":"Cadarette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joann K.","family":"Ban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorraine","family":"Lipscombe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven A.","family":"Narod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Kotsopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,13]]},"reference":[{"key":"225_CR1","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/ijcp.12022","volume":"66","author":"DA Hanley","year":"2012","unstructured":"Hanley, D. A., Adachi, J. D., Bell, A. & Brown, V. Denosumab: mechanism of action and clinical outcomes. Int. J. Clin. Pract. 66, 1139\u20131146 (2012).","journal-title":"Int. J. Clin. Pract."},{"key":"225_CR2","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1159\/000371845","volume":"61","author":"V Nagy","year":"2015","unstructured":"Nagy, V. & Penninger, J. M. The RANKL-RANK Story. Gerontology 61, 534\u2013542 (2015).","journal-title":"Gerontology"},{"key":"225_CR3","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings, S. R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756\u2013765 (2009).","journal-title":"N. Engl. J. Med."},{"key":"225_CR4","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s00198-014-3023-8","volume":"26","author":"AM Burden","year":"2015","unstructured":"Burden, A. M., Tadrous, M., Calzavara, A. & Cadarette, S. M. Uptake and characteristics of zoledronic acid and denosumab patients and physicians in Ontario, Canada: impact of drug formulary access. Osteoporos. Int. 26, 1525\u20131533 (2015).","journal-title":"Osteoporos. Int."},{"key":"225_CR5","unstructured":"Ban J. K., et al editors. Over 63,700 ontario seniors have initiated denosumab: user characteristics and persistence with therapy. J. Popul. Ther. Clin. Pharmacol. 24(3):e51\u2013e78; Ontario 26, 2017. Page 31. 2017 (Abstract)."},{"key":"225_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0092-8674(00)00103-3","volume":"103","author":"JE Fata","year":"2000","unstructured":"Fata, J. E. et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103, 41\u201350 (2000).","journal-title":"Cell"},{"key":"225_CR7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nature09387","volume":"468","author":"D Schramek","year":"2010","unstructured":"Schramek, D. et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468, 98\u2013102 (2010).","journal-title":"Nature"},{"key":"225_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nature09495","volume":"468","author":"E Gonzalez-Suarez","year":"2010","unstructured":"Gonzalez-Suarez, E. et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468, 103\u2013107 (2010).","journal-title":"Nature"},{"key":"225_CR9","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nature09027","volume":"465","author":"ML Asselin-Labat","year":"2010","unstructured":"Asselin-Labat, M. L. et al. Control of mammary stem cell function by steroid hormone signalling. Nature 465, 798\u2013802 (2010).","journal-title":"Nature"},{"key":"225_CR10","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nature09091","volume":"465","author":"PA Joshi","year":"2010","unstructured":"Joshi, P. A. et al. Progesterone induces adult mammary stem cell expansion. Nature 465, 803\u2013807 (2010).","journal-title":"Nature"},{"key":"225_CR11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","volume":"386","author":"M Gnant","year":"2015","unstructured":"Gnant, M. et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386, 433\u2013443 (2015).","journal-title":"Lancet"},{"key":"225_CR12","doi-asserted-by":"crossref","unstructured":"Gnant M. P. G., et al, on behalf of the Austrian Breast and Colorectal Cancer StudyGroup. The impact of adjuvant denosumab on disease-free survival: results from 3,425 postmenopausal patients of the ABCSG-18 trial. San Antonio Breast Cancer Symposium; 2015.","DOI":"10.1158\/1538-7445.SABCS15-S2-02"},{"key":"225_CR13","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1016\/S1470-2045(17)30536-3","volume":"18","author":"J Cuzick","year":"2017","unstructured":"Cuzick, J. Preventive therapy for cancer. Lancet Oncol. 18, e472\u2013e482 (2017).","journal-title":"Lancet Oncol."},{"key":"225_CR14","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/annonc\/mdv590","volume":"27","author":"SG Smith","year":"2016","unstructured":"Smith, S. G. et al. Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. Ann. Oncol. 27, 575\u2013590 (2016).","journal-title":"Ann. Oncol."},{"key":"225_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10549-016-4029-z","volume":"161","author":"J Kotsopoulos","year":"2017","unstructured":"Kotsopoulos, J., Singer, C. & Narod, S. A. Can we prevent BRCA1-associated breast cancer by RANKL inhibition? Breast Cancer Res. Treat. 161, 11\u201316 (2017).","journal-title":"Breast Cancer Res. Treat."},{"key":"225_CR16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/0895-4356(88)90052-2","volume":"41","author":"SC Robles","year":"1988","unstructured":"Robles, S. C., Marrett, L. D., Clarke, E. A. & Risch, H. A. An application of capture-recapture methods to the estimation of completeness of cancer registration. J. Clin. Epidemiol. 41, 495\u2013501 (1988).","journal-title":"J. Clin. Epidemiol."},{"key":"225_CR17","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s00198-010-1329-8","volume":"22","author":"SM Cadarette","year":"2011","unstructured":"Cadarette, S. M., Jaglal, S. B., Raman-Wilms, L., Beaton, D. E. & Paterson, J. M. Osteoporosis quality indicators using healthcare utilization data. Osteoporos. Int. 22, 1335\u20131342 (2011).","journal-title":"Osteoporos. Int."},{"key":"225_CR18","unstructured":"Care OMoHaL-T. Ontario Public Drug Programs - Exceptional Access Program. Available from http:\/\/health.gov.on.ca\/en\/pro\/programs\/drugs ."},{"key":"225_CR19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10549-013-2431-3","volume":"138","author":"X Qu","year":"2013","unstructured":"Qu, X. et al. Bone mineral density and risk of breast cancer in postmenopausal women. Breast Cancer Res. Treat. 138, 261\u2013271 (2013).","journal-title":"Breast Cancer Res. Treat."},{"key":"225_CR20","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1200\/JCO.2010.28.1113","volume":"28","author":"G Rennert","year":"2010","unstructured":"Rennert, G., Pinchev, M. & Rennert, H. S. Use of bisphosphonates and risk of postmenopausal breast cancer. J. Clin. Oncol. 28, 3577\u20133581 (2010).","journal-title":"J. Clin. Oncol."},{"key":"225_CR21","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/sj.bjc.6605555","volume":"102","author":"PA Newcomb","year":"2010","unstructured":"Newcomb, P. A., Trentham-Dietz, A. & Hampton, J. M. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br. J. Cancer 102, 799\u2013802 (2010).","journal-title":"Br. J. Cancer"},{"key":"225_CR22","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s00198-011-1771-2","volume":"23","author":"SM Cadarette","year":"2012","unstructured":"Cadarette, S. M. et al. Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage. Osteoporos. Int. 23, 1475\u20131480 (2012).","journal-title":"Osteoporos. Int."},{"key":"225_CR23","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/j.1464-5491.2011.03568.x","volume":"29","author":"PC Austin","year":"2012","unstructured":"Austin, P. C., Shah, B. R., Newman, A. & Anderson, G. M. Using the Johns Hopkins\u2019 Aggregated Diagnosis Groups (ADGs) to predict 1-year mortality in population-based cohorts of patients with diabetes in Ontario, Canada. Diabet. Med. 29, 1134\u20131141 (2012).","journal-title":"Diabet. Med."},{"key":"225_CR24","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/sim.2580","volume":"26","author":"PC Austin","year":"2007","unstructured":"Austin, P. C., Grootendorst, P. & Anderson, G. M. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat. Med. 26, 734\u2013753 (2007).","journal-title":"Stat. Med."},{"key":"225_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-014-2852-7","volume":"144","author":"KN Anderson","year":"2014","unstructured":"Anderson, K. N., Schwab, R. B. & Martinez, M. E. Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res. Treat. 144, 1\u201310 (2014).","journal-title":"Breast Cancer Res. Treat."},{"key":"225_CR26","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/cr.2016.69","volume":"26","author":"V Sigl","year":"2016","unstructured":"Sigl, V. et al. RANKL\/RANK control Brca1 mutation-driven mammary tumors. Cell Res. 26, 761\u2013774 (2016).","journal-title":"Cell Res."},{"key":"225_CR27","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/nm.4118","volume":"22","author":"E Nolan","year":"2016","unstructured":"Nolan, E. et al. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat. Med. 22, 933\u2013939 (2016).","journal-title":"Nat. Med."},{"key":"225_CR28","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1002\/ijc.23340","volume":"122","author":"KA Metcalfe","year":"2008","unstructured":"Metcalfe, K. A. et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. International journal of cancer. J. Int. Cancer 122, 2017\u20132022 (2008).","journal-title":"J. Int. Cancer"},{"key":"225_CR29","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/nrclinonc.2013.169","volume":"10","author":"N Gronich","year":"2013","unstructured":"Gronich, N. & Rennert, G. Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat. Rev. Clin. Oncol. 10, 625\u2013642 (2013).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"225_CR30","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/annonc\/mdm442","volume":"19","author":"M Aapro","year":"2008","unstructured":"Aapro, M. et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Annals of oncology: official journal of the European Society for. Ann. Oncol. 19, 420\u2013432 (2008).","journal-title":"Ann. Oncol."},{"key":"225_CR31","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1200\/JCO.2016.71.4337","volume":"35","author":"A Fournier","year":"2017","unstructured":"Fournier, A. et al. Use of bisphosphonates and risk of breast cancer in a French cohort of postmenopausal women. J. Clin. Oncol. 35, 3230\u20133239 (2017).","journal-title":"J. Clin. Oncol."},{"key":"225_CR32","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.clinthera.2012.04.009","volume":"34","author":"JM Gamble","year":"2012","unstructured":"Gamble, J. M., McAlister, F. A., Johnson, J. A. & Eurich, D. T. Restrictive drug coverage policies can induce substantial drug exposure misclassification in pharmacoepidemiologic studies. Clin. Ther. 34, 1379\u20131386 e3 (2012).","journal-title":"Clin. Ther."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0225-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0225-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0225-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:03:07Z","timestamp":1684616587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0225-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["225"],"URL":"https:\/\/doi.org\/10.1038\/s41416-018-0225-4","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"5 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was supported by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The data analyzed for the current study are available upon reasonable request from the corresponding author.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"This study was approved by the Research Ethics Boards at Sunnybrook Health Sciences Centre and Women\u2019s College Hospital. Given the retrospective nature of this study, informed consent was waived. This study was performed in accordance with the Declaration of Helsinki","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"JK is the recipient of a Tier II Canada Research Chair. SAN is the recipient of a Tier I Canada Research Chair. VG is supported by the Canadian Institutes of Health Research (CIHR) Frederick Banting and Charles Best Doctoral Research Award.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Note"}}]}}